Y. Wittrant, S. Théoleyre, and C. Chipoy, new therapeutic targets in bone tumours and associated osteolysis Molecular mechanisms of tumor-bone interactions in osteolytic metastases, Biochim. Biophys. Acta Crit. Rev. Eukaryot Gene Exp, vol.1704, issue.10, pp.49-57, 2000.

D. Heymann, B. Ory, F. Gouin, J. Green, F. Rédini et al., Bisphosphonates: new therapeutic agents for the treatment of bone tumors Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy, Trends Mol Med Osteoporos Int, vol.105, issue.19, pp.337-380, 2004.

A. Hirbe, A. Roelofs, and D. Floyd, The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts, Bone, vol.44, issue.5, pp.908-924, 2009.
DOI : 10.1016/j.bone.2009.01.010

A. Jung, S. Bisaz, H. Fleisch, E. Silberstein, E. Saenger et al., The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals, Bone Cancer: Progression and Therapeutic approaches, pp.269-80, 1973.
DOI : 10.1007/BF02547227

H. Schirrmeister, C. Arslandemir, C. Hoefnagel, P. Bruning, P. Cohen et al., Diagnosis of skeletal metastases in malignant extraskeletal cancers Heymann Dominique Detection of lung metastases from osteosarcoma by scintigraphy using 99mTc-methylene diphosphonate, Bone Cancer: Progression and Therapeutic approaches, pp.283-94, 1981.

M. Fellner, R. Baum, and V. Kubíek, CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study, Eur J Nucl Med Mol Imaging, vol.12

T. Anada, Y. Takeda, Y. Honda, K. Sakurai, and O. Suzuki, Synthesis of calcium phosphate-binding liposome for drug delivery, Bioorganic & Medicinal Chemistry Letters, vol.19, issue.15, pp.4148-50, 2009.
DOI : 10.1016/j.bmcl.2009.05.117

M. Eisenhut, Iodine-131-labeled diphosphonates for the palliative treatment of bone metastases: I. Organ distribution and kinetics of I-131 BDP3 in rats, J. Nucl. Med, vol.2514, pp.1356-61, 1984.

N. Tsushima, M. Yabuki, and H. Harada, Tissue distribution and pharmacological potential of SM-16896, a novel oestrogenbisphosphonate hybrid compound 186Re-HEDP in the treatment of patients with inoperable osteosarcoma Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India Osteoclast-rich lesions of bone: a clinical and molecular overview, Bone Cancer, pp.27-37, 2000.

M. Werner, Giant cell tumour of bone: morphological, biological and histogenetical aspects, International Orthopaedics, vol.11, issue.6, pp.484-493, 2006.
DOI : 10.1007/s00264-006-0215-7

G. Atkins, D. Haynes, and S. Graves, Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors, Journal of Bone and Mineral Research, vol.11, issue.Suppl 8, pp.640-649, 2000.
DOI : 10.1359/jbmr.2000.15.4.640

M. Rogers, S. Gordon, and H. Benford, Cellular and molecular mechanisms of action of bisphosphonates mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours, Cancer Curr. Med. Chem, vol.882122, issue.14, pp.2961-78, 2000.

F. Coxon, M. Helfrich, and R. Van-'t-hof, Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298, Journal of Bone and Mineral Research, vol.108, issue.8, pp.1467-76, 2000.
DOI : 10.1359/jbmr.2000.15.8.1467

S. Colucci, V. Minielli, and G. Zambonin, Alendronate reduces adhesion of human osteoclast-like cells to bone and bone proteincoated surfaces, Calcif Tissue Int, vol.6324, pp.230-235, 1998.

X. Wang, S. Yu, Z. Yang, Y. Cheng, L. Huang et al., Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone, Chin J Dent Res Ultrastruct Pathol Clin. Orthop Relat Res Calcif Tissue Int, vol.327, issue.75, pp.26-32, 2000.

P. Zwolak, J. Manivel, and P. Jasinski, Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma , and renal cell carcinoma cell lines Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature A new bisphosphonate treatment option for giant cell tumors, J Bone Joint Surg Am J Med Assoc Thai Oncol Rep, vol.922930, issue.8, pp.162-170, 2001.

L. Tse, K. Wong, S. Kumta, L. Huang, T. Chow et al., Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone Epidemiology of primary bone tumors and economical aspects of bone metastases, Bone Cancer: Progression and Therapeutic approaches, pp.68-73, 1997.

O. Delattre, J. Zucman, and T. Melot, The Ewing Family of Tumors -- A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts, New England Journal of Medicine, vol.331, issue.5, pp.294-303, 1994.
DOI : 10.1056/NEJM199408043310503

N. Riggi, M. Suva, and I. Stamenkovic, Ewing???s sarcoma origin: from duel to duality, Expert Review of Anticancer Therapy, vol.9, issue.8, pp.1025-1055, 2009.
DOI : 10.1586/era.09.81

J. Khoury, Ewing???s Sarcoma Family of Tumors, Bone Cancer: Progression and Therapeutic approaches, pp.235-50, 2010.
DOI : 10.1016/B978-0-12-374895-9.00020-7

P. Mackie, J. Fisher, H. Zhou, P. Choong, J. Sonnemann et al., Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro, Br J Cancer Anticancer Drugs, vol.843940, issue.12, pp.951-959, 2001.

M. Kanamori, H. Matsui, A. Maeda, K. Yudoh, H. Tsuji et al., Effects of ethane-1-hydroxy-1, 1 diphosphonate on Dunn osteosarcoma cells, J Exp Clin Cancer Res, vol.1641, pp.39-43, 1997.

B. Kubista, K. Trieb, and F. Sevelda, Anticancer effects of zoledronic acid against human osteosarcoma cells, Journal of Orthopaedic Research, vol.2, issue.6, pp.1145-52, 2006.
DOI : 10.1002/jor.20129

N. Horie, H. Murata, and Y. Nishigaki, The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis, Cancer Letters, vol.238, issue.1, pp.111-119, 2006.
DOI : 10.1016/j.canlet.2005.06.041

R. Tenta, N. Pitulis, and D. Tiblalexi, Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gammadichloromethylene ) triphosphate, by mammalian cells in vitro Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis, Horm Metab Res J Bone Miner Res Bone, vol.404446, issue.33, pp.737-782, 1997.

R. Inoue, N. Matsuki, G. Jing, T. Kanematsu, K. Abe et al., The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells

B. Ory, F. Blanchard, S. Battaglia, F. Gouin, F. Rédini et al., Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma Status, Molecular Pharmacology, vol.71, issue.1, pp.333-376, 2007.
DOI : 10.1124/mol.106.028837

T. Iguchi, Y. Miyakawa, and K. Saito, Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines Risedronate inhibits human osteosarcoma cell invasion, Int J Oncol Eur J Pharmacol Pediatr Blood Cancer J Exp Clin Cancer Res, vol.31495152, issue.28, pp.285-91, 2004.

P. Heikkilä, O. Teronen, and M. Hirn, Inhibition of matrix metal- loproteinase-14 in osteosarcoma cells by clodronate Modulation of cytosolic calcium levels in osteoblast-like osteosarcoma cells by olpadronate and its amino-derivative IG-9402 Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells, J Surg Res Calcif Tissue Int J Cell Mol Med, vol.1115455, issue.12, pp.45-52, 2003.

F. Wingen, H. Sterz, and H. Blum, Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]- 1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, [57] Dass CR, Choong PFM. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model, pp.209-228, 1986.

K. Koto, N. Horie, and S. Kimura, Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model, Cancer Lett Clin Cancer Res Int J Cancer, vol.274, issue.127, pp.271-279, 2009.

N. Giuliani, M. Pedrazzoni, G. Passeri, G. Girasole, R. Tenta et al., Bisphosphonates inhibit IL-6 production by human osteoblast-like cells Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells, Mereuta OM, Saglio F, et al. Interactions between osteosarcoma cell lines and dendritic cells immune function: An in vitro study, pp.38-41, 1998.

C. Chauvin, J. Philippeau, and C. Hémont, Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats, Cancer Research, vol.68, issue.22, pp.9433-9473, 2008.
DOI : 10.1158/0008-5472.CAN-08-0104

M. Benassi, A. Chiechi, and F. Ponticelli, Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells, Cancer Lett Anticancer Res Cancer Chemother Pharmacol, vol.2506769, issue.62, pp.194-205, 2007.

D. Heymann, B. Ory, and F. Blanchard, Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.
DOI : 10.1016/j.bone.2005.02.020

N. Horie, H. Murata, and S. Kimura, Combined effects of a thirdgeneration bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs, Br J Cancer J Vet Intern Med, vol.967172, issue.15, pp.255-61, 2001.

J. Ashton, J. Farese, R. Milner, L. Lee-ambrose, and J. Van-gilder, Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs, American Journal of Veterinary Research, vol.66, issue.5, pp.885-91, 2005.
DOI : 10.2460/ajvr.2005.66.885

J. Farese, J. Ashton, R. Milner, L. Ambrose, V. Gilder et al., The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis, In Vitro Cell Dev Biol Anim Vet. Rec J Vet Intern Med J Vet Intern Med, vol.407477, issue.22, pp.113-120, 2000.

E. Spugnini, B. Vincenzi, and G. Caruso, Zoledronic acid for the treatment of appendicular osteosarcoma in a dog Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro, J Small Anim Pract J Vet Intern Med Anticancer Drugs, vol.507980, issue.14, pp.44-46, 2003.

Z. Zhou, H. Guan, X. Duan, E. M. Kleinerman, F. Lamoureux et al., Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases, Cancer Cell Mol Life Sci, vol.158182, issue.64, pp.1713-1733, 2005.

H. Siden, H. Jaffe, . Chondrosarcoma, and . Bone, The boy who refused an IV: a case report of subcutaneous clodronate for bone pain in a child with Ewing Sarcoma, Journal of Medical Case Reports, vol.164, issue.9, pp.553-89, 1943.
DOI : 10.1007/s00431-005-1698-8

D. Dahlin, K. Unni, . Bone, A. Streibuerger, J. Hardes et al., Sprinfield: IL: Charles C Thomas Chondrosarcoma of bone: diagnosis and therapy Risk factors for survival and local control in chondrosarcoma of bone Chondrosarcoma: a clinicopathologic and statistical analysis, Bone Cancer: Progression and Therapeutic approaches, pp.407-422, 1980.

T. Lai, S. Hsu, T. Li, H. Hsu, J. Lin et al., Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line, Acta Pharmacologica Sinica, vol.40, issue.8, pp.1231-1236, 2007.
DOI : 10.2165/00003495-200059030-00001

M. Susa, T. Morii, and H. Yabe, Alendronate inhibits growth of high-grade chondrosarcoma cells Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival, Anticancer Res Int J Cancer, vol.2991, issue.119, pp.1879-88, 2006.

T. Kubo, S. Shimose, and T. Matsuo, Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells, Journal of Orthopaedic Research, vol.88, issue.6, pp.1138-1182, 2006.
DOI : 10.1002/jor.20177

L. Montella, R. Addeo, and V. Faiola, Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports, Journal of Experimental & Clinical Cancer Research, vol.28, issue.1, pp.7-93, 2009.
DOI : 10.1186/1756-9966-28-7

L. Montella, C. Merola, G. Merola, L. Petillo, and G. Palmieri, Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis, Journal of Bone and Mineral Metabolism, vol.94, issue.suppl 4, pp.110-113, 2009.
DOI : 10.1007/s00774-008-0001-2

S. Allaudin, G. Alan, and S. Zafar, Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, vol.10895, pp.1-8, 2009.

S. Fedele, N. Kumar, R. Davies, J. Fiske, S. Greening et al., Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment, Oral Dis Hematology, vol.1597, issue.10, pp.527-564, 2005.

P. Tsagozis, F. Eriksson, P. Pisa, Z. Wu, N. Van-rooijen et al., Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages Targeting tumorassociated macrophages in an orthotopic murine model of diffuse malignant mesothelioma, Cancer Immunol Immunther Mol Cancer Ther, vol.5799, pp.1451-1460, 2008.

D. Ribatti, . Maruotti, and B. Nico, Clodronate inhibits angiogenesis in vitro and in vivo, Oncology Reports, pp.1109-1121, 2008.
DOI : 10.3892/or.19.5.1109

D. Santini, B. Vincenzi, and S. Galluzzo, Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients, Clinical Cancer Research, vol.13, issue.15, pp.4482-4488, 2007.
DOI : 10.1158/1078-0432.CCR-07-0551

U. Bäckman, A. Svensson, R. Chritofferson, and F. Azarbayjani, The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth with interfering with tumour angiogenesis, Anticancer Res, vol.28, pp.1551-1558, 2008.

F. Cackowski and G. Roodman, Perspective on the Osteoclast: An Angiogenic Cell?, Annals of the New York Academy of Sciences, vol.1117, issue.1, pp.12-25, 2007.
DOI : 10.1196/annals.1402.073